Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis
- 1.1k Downloads
Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated.
Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls.
Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021).
PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.
KeywordsAcute exacerbation Idiopathic pulmonary fibrosis Lung cancer Surgery Pirfenidone
- 4.Yoshimura K, Miyamoto A, Uruga H, Morokawa N, Beika Y, Kishi K. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2008. 2009:77–81.Google Scholar
- 8.Kawabata Y, Hoshi E, Ubukata M, Takayanagi N, Sugita Y, Aoyama K, et al. Histological changes are background factors in acute exacerbation of usual interstitial pneumonia pattern/lesions following lung resection (in Japanese with English abstract). Haigan (Jpn J Lung Cancer). 2006;46:329–36.CrossRefGoogle Scholar
- 9.Matsubara O, Ohba T, Ninomiya H, Ishikawa Y, Mark E. Histological characteristics in the prediction of acute exacerbation of idiopathic pulmonary fibrosis (IPF) following surgery for primary lung cancer. Mod Pathol. 2009;22:358A.Google Scholar
- 14.Chiba H, Natsuzaka M, Shiratori M, Mori M, Takahashi H. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2010. 2011:143–51.Google Scholar
- 21.Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection (in Japanese with English abstract). Nihon Geka Gakkai Zasshi (Jpn J Surg). 2004;105:757–62.Google Scholar
- 26.Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161–5.CrossRefPubMedGoogle Scholar